Literature DB >> 33660966

Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?

Robert Marčec, Robert Likić1.   

Abstract

Entities:  

Year:  2021        PMID： 33660966      PMCID： PMC7976881     

Source DB:  PubMed          Journal:  Croat Med J        ISSN： 0353-9504            Impact factor:   1.351


× No keyword cloud information.
  32 in total

1.  Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells.

Authors:  Tamaki Ishima; Yuko Fujita; Kenji Hashimoto
Journal:  Eur J Pharmacol       Date:  2014-02-05       Impact factor: 4.432

2.  Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis.

Authors:  Dorian A Rosen; Scott M Seki; Anthony Fernández-Castañeda; Rebecca M Beiter; Jacob D Eccles; Judith A Woodfolk; Alban Gaultier
Journal:  Sci Transl Med       Date:  2019-02-06       Impact factor: 17.956

3.  Determinants of COVID-19 vaccine acceptance in the US.

Authors:  Amyn A Malik; SarahAnn M McFadden; Jad Elharake; Saad B Omer
Journal:  EClinicalMedicine       Date:  2020-08-12

4.  Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement.

Authors:  P Celada; M Dolera; E Alvarez; F Artigas
Journal:  J Affect Disord       Date:  1992-08       Impact factor: 4.839

Review 5.  Drug repurposing: progress, challenges and recommendations.

Authors:  Sudeep Pushpakom; Francesco Iorio; Patrick A Eyers; K Jane Escott; Shirley Hopper; Andrew Wells; Andrew Doig; Tim Guilliams; Joanna Latimer; Christine McNamee; Alan Norris; Philippe Sanseau; David Cavalla; Munir Pirmohamed
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

6.  Evaluation of the Effect of Antidepressant Drug, Fluvoxamine, on Cyclooxygenase-2 Protein Expression in Lipopolysaccharide-stimulated Macrophages.

Authors:  Hajar Naji Esfahani; Laleh Rafiee; Shaghayegh Haghjooy Javanmard
Journal:  Adv Biomed Res       Date:  2019-01-31

7.  The effect of COVID-19 lockdown on lifestyle and mood in Croatian general population: a cross-sectional study.

Authors:  Zoran Đogaš; Linda Lušić Kalcina; Ivana Pavlinac Dodig; Sijana Demirović; Katarina Madirazza; Maja Valić; Renata Pecotić
Journal:  Croat Med J       Date:  2020-08-31       Impact factor: 1.351

8.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.

Authors:  David M Weinreich; Sumathi Sivapalasingam; Thomas Norton; Shazia Ali; Haitao Gao; Rafia Bhore; Bret J Musser; Yuhwen Soo; Diana Rofail; Joseph Im; Christina Perry; Cynthia Pan; Romana Hosain; Adnan Mahmood; John D Davis; Kenneth C Turner; Andrea T Hooper; Jennifer D Hamilton; Alina Baum; Christos A Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Anita Kohli; Yessica Sachdeva; Ximena Graber; Bari Kowal; Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos
Journal:  N Engl J Med       Date:  2020-12-17       Impact factor: 91.245

9.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.

Authors:  John H Stone; Matthew J Frigault; Naomi J Serling-Boyd; Ana D Fernandes; Liam Harvey; Andrea S Foulkes; Nora K Horick; Brian C Healy; Ruta Shah; Ana Maria Bensaci; Ann E Woolley; Sarah Nikiforow; Nina Lin; Manish Sagar; Harry Schrager; David S Huckins; Matthew Axelrod; Michael D Pincus; Jorge Fleisher; Chana A Sacks; Michael Dougan; Crystal M North; Yuan-Di Halvorsen; Tara K Thurber; Zeina Dagher; Allison Scherer; Rachel S Wallwork; Arthur Y Kim; Sara Schoenfeld; Pritha Sen; Tomas G Neilan; Cory A Perugino; Sebastian H Unizony; Deborah S Collier; Mark A Matza; Janeth M Yinh; Kathryn A Bowman; Eric Meyerowitz; Amna Zafar; Zsofia D Drobni; Marcy B Bolster; Minna Kohler; Kristin M D'Silva; Jonathan Dau; Megan M Lockwood; Caroline Cubbison; Brittany N Weber; Michael K Mansour
Journal:  N Engl J Med       Date:  2020-10-21       Impact factor: 176.079
View more
  3 in total

Review 1.  Fluvoxamine for the treatment of COVID-19.

Authors:  John Lz Nyirenda; Mario Sofroniou; Ingrid Toews; Agata Mikolajewska; Cornelius Lehane; Ina Monsef; Aesha Abu-Taha; Andy Maun; Miriam Stegemann; Christine Schmucker
Journal:  Cochrane Database Syst Rev       Date:  2022-09-14

2.  Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.

Authors:  Martina Calusic; Robert Marcec; Lea Luksa; Ivan Jurkovic; Natasa Kovac; Slobodan Mihaljevic; Robert Likic
Journal:  Br J Clin Pharmacol       Date:  2021-12-01       Impact factor: 3.716

3.  Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients?

Authors:  Robert Marcec; Robert Likic
Journal:  Clin Pharmacokinet       Date:  2022-07-23       Impact factor: 5.577
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.